Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (501-510 of 740) with videos related to

Pageof 74
Sort By:
Blood Cancer Journal|October 6, 2018
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupLia A Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, et al.
Blood|May 12, 2016
Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosisEfstathios Kastritis, Ioannis Papassotiriou, Evangelos Terpos, et al.
Haematologica|February 22, 2008
Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomibKonstantinos Anargyrou, Evangelos Terpos, Theodoros P Vassilakopoulos, et al.
Advances in Therapy|October 31, 2018
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple MyelomaXu Steven Xu, Meletios A Dimopoulos, Pieter Sonneveld, et al.
Leukemia & Lymphoma|December 15, 2016
Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimensDimitrios C Ziogas, Efstathios Kastritis, Evangelos Terpos, et al.
Frontiers in Immunology|October 22, 2021
Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic <i>Versus</i> Clinical InfectionPetros P Sfikakis, Kleio-Maria Verrou, Giannis Ampatziadis-Michailidis, et al.
American Journal of Hematology|May 23, 2022
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysisMeletios A Dimopoulos, Philippe Moreau, Bradley Augustson, et al.
Blood Advances|November 4, 2022
Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrationsKylee H Maclachlan, Tina Bagratuni, Efstathios Kastritis, et al.
Leukemia|July 25, 2018
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasiasMaria Gavriatopoulou, Pellegrino Musto, Jo Caers, et al.
American Journal of Hematology|July 19, 2025
Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single InstitutionMeletios A Dimopoulos, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, et al.
Pageof 74

Showing results (501-510 of 740) with videos related to

Sort By:
Pageof 74
Blood Cancer Journal|October 6, 2018
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupLia A Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, et al.
Blood|May 12, 2016
Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosisEfstathios Kastritis, Ioannis Papassotiriou, Evangelos Terpos, et al.
Haematologica|February 22, 2008
Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomibKonstantinos Anargyrou, Evangelos Terpos, Theodoros P Vassilakopoulos, et al.
Advances in Therapy|October 31, 2018
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple MyelomaXu Steven Xu, Meletios A Dimopoulos, Pieter Sonneveld, et al.
Leukemia & Lymphoma|December 15, 2016
Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimensDimitrios C Ziogas, Efstathios Kastritis, Evangelos Terpos, et al.
Frontiers in Immunology|October 22, 2021
Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic <i>Versus</i> Clinical InfectionPetros P Sfikakis, Kleio-Maria Verrou, Giannis Ampatziadis-Michailidis, et al.
American Journal of Hematology|May 23, 2022
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysisMeletios A Dimopoulos, Philippe Moreau, Bradley Augustson, et al.
Blood Advances|November 4, 2022
Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrationsKylee H Maclachlan, Tina Bagratuni, Efstathios Kastritis, et al.
Leukemia|July 25, 2018
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasiasMaria Gavriatopoulou, Pellegrino Musto, Jo Caers, et al.
American Journal of Hematology|July 19, 2025
Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single InstitutionMeletios A Dimopoulos, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, et al.
Pageof 74